IL1B and myeloproliferative disorder: Our data is in-line with these studies, as we also observed increased TGFβ1 serum levels in MPN patients (Supplementary Fig. 3) and reduced TGFβ1 levels in bone marrow of VF mice with genetic or pharmacological inhibition of IL-1β (Supplementary Figs. 7b and 10b).